 Finally, the patient will be evaluated for more distant sites of metastatic disease, most typically with brain imaging and or scans of the bones.The survival rates for stages I through IV decrease significantly due to the advancement of the disease.For stage I, the five-year survival rate is 47%, stage II is 30%, stage III is 10%, and stage IV is 1%.